-
1
-
-
1542471132
-
AIDS vaccine fails in Thai trial
-
McCarthy M. AIDS vaccine fails in Thai trial. Lancet 362 9397 (2003) 1728
-
(2003)
Lancet
, vol.362
, Issue.9397
, pp. 1728
-
-
McCarthy, M.1
-
2
-
-
0037362934
-
HIV vaccine fails in phase 3 trial
-
McCarthy M. HIV vaccine fails in phase 3 trial. Lancet 361 9359 (2003) 755-756
-
(2003)
Lancet
, vol.361
, Issue.9359
, pp. 755-756
-
-
McCarthy, M.1
-
3
-
-
35148818748
-
AIDS research. Promising AIDS vaccine's failure leaves field reeling
-
Cohen J. AIDS research. Promising AIDS vaccine's failure leaves field reeling. Science 318 5847 (2007) 28-29
-
(2007)
Science
, vol.318
, Issue.5847
, pp. 28-29
-
-
Cohen, J.1
-
4
-
-
4644249733
-
Predicting the impact of a nonsterilizing vaccine against human immunodeficiency virus
-
Davenport M.P., Ribeiro R.M., Chao D.L., and Perelson A.S. Predicting the impact of a nonsterilizing vaccine against human immunodeficiency virus. J Virol 78 20 (2004) 11340-11351
-
(2004)
J Virol
, vol.78
, Issue.20
, pp. 11340-11351
-
-
Davenport, M.P.1
Ribeiro, R.M.2
Chao, D.L.3
Perelson, A.S.4
-
5
-
-
4344693298
-
Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160
-
Lee D., Graham B.S., Chiu Y.L., Gilbert P.B., McElrath M.J., Belshe R.B., et al. Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160. J Infect Dis 190 5 (2004) 903-907
-
(2004)
J Infect Dis
, vol.190
, Issue.5
, pp. 903-907
-
-
Lee, D.1
Graham, B.S.2
Chiu, Y.L.3
Gilbert, P.B.4
McElrath, M.J.5
Belshe, R.B.6
-
6
-
-
13944254982
-
Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection
-
Flynn N.M., Forthal D.N., Harro C.D., Judson F.N., Mayer K.H., and Para M.F. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 191 5 (2005) 654-665
-
(2005)
J Infect Dis
, vol.191
, Issue.5
, pp. 654-665
-
-
Flynn, N.M.1
Forthal, D.N.2
Harro, C.D.3
Judson, F.N.4
Mayer, K.H.5
Para, M.F.6
-
7
-
-
0022511286
-
Antibody-dependent enhancement of viral infectivity
-
Porterfield J.S. Antibody-dependent enhancement of viral infectivity. Adv Virus Res 31 (1986) 335-355
-
(1986)
Adv Virus Res
, vol.31
, pp. 335-355
-
-
Porterfield, J.S.1
-
8
-
-
85013269265
-
Enhancing antibodies in HIV infection
-
Fust G. Enhancing antibodies in HIV infection. Parasitology 115 Suppl (1997) S127-S140
-
(1997)
Parasitology
, vol.115
, Issue.SUPPL
-
-
Fust, G.1
-
9
-
-
0037257790
-
Antibody-dependent enhancement of virus infection and disease
-
Tirado S.M., and Yoon K.J. Antibody-dependent enhancement of virus infection and disease. Viral Immunol 16 1 (2003) 69-86
-
(2003)
Viral Immunol
, vol.16
, Issue.1
, pp. 69-86
-
-
Tirado, S.M.1
Yoon, K.J.2
-
10
-
-
0018580825
-
In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody
-
Halstead S.B. In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J Infect Dis 140 4 (1979) 527-533
-
(1979)
J Infect Dis
, vol.140
, Issue.4
, pp. 527-533
-
-
Halstead, S.B.1
-
11
-
-
0014775305
-
Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered
-
Halstead S.B., Nimmannitya S., and Cohen S.N. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J Biol Med 42 5 (1970) 311-328
-
(1970)
Yale J Biol Med
, vol.42
, Issue.5
, pp. 311-328
-
-
Halstead, S.B.1
Nimmannitya, S.2
Cohen, S.N.3
-
12
-
-
0023818748
-
Pathogenesis of dengue: challenges to molecular biology
-
Halstead S.B. Pathogenesis of dengue: challenges to molecular biology. Science 239 4839 (1988) 476-481
-
(1988)
Science
, vol.239
, Issue.4839
, pp. 476-481
-
-
Halstead, S.B.1
-
13
-
-
0023845514
-
A prospective study of dengue infections in Bangkok
-
Burke D.S., Nisalak A., Johnson D.E., and Scott R.M. A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg 38 1 (1988) 172-180
-
(1988)
Am J Trop Med Hyg
, vol.38
, Issue.1
, pp. 172-180
-
-
Burke, D.S.1
Nisalak, A.2
Johnson, D.E.3
Scott, R.M.4
-
14
-
-
0024565393
-
Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever
-
Kliks S.C., Nisalak A., Brandt W.E., Wahl L., and Burke D.S. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 40 4 (1989) 444-451
-
(1989)
Am J Trop Med Hyg
, vol.40
, Issue.4
, pp. 444-451
-
-
Kliks, S.C.1
Nisalak, A.2
Brandt, W.E.3
Wahl, L.4
Burke, D.S.5
-
15
-
-
33846079822
-
Of cascades and perfect storms: the immunopathogenesis of dengue haemorrhagic fever-dengue shock syndrome (DHF/DSS)
-
Pang T., Cardosa M.J., and Guzman M.G. Of cascades and perfect storms: the immunopathogenesis of dengue haemorrhagic fever-dengue shock syndrome (DHF/DSS). Immunol Cell Biol 85 1 (2007) 43-45
-
(2007)
Immunol Cell Biol
, vol.85
, Issue.1
, pp. 43-45
-
-
Pang, T.1
Cardosa, M.J.2
Guzman, M.G.3
-
16
-
-
0022450456
-
A new mechanism for the neutralization of enveloped viruses by antiviral antibody
-
Gollins S.W., and Porterfield J.S. A new mechanism for the neutralization of enveloped viruses by antiviral antibody. Nature 321 6067 (1986) 244-246
-
(1986)
Nature
, vol.321
, Issue.6067
, pp. 244-246
-
-
Gollins, S.W.1
Porterfield, J.S.2
-
17
-
-
0033970916
-
Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity
-
Vaughn D.W., Green S., Kalayanarooj S., Innis B.L., Nimmannitya S., Suntayakorn S., et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 181 1 (2000) 2-9
-
(2000)
J Infect Dis
, vol.181
, Issue.1
, pp. 2-9
-
-
Vaughn, D.W.1
Green, S.2
Kalayanarooj, S.3
Innis, B.L.4
Nimmannitya, S.5
Suntayakorn, S.6
-
18
-
-
1642415963
-
Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand
-
Endy T.P., Nisalak A., Chunsuttitwat S., Vaughn D.W., Green S., Ennis F.A., et al. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis 189 6 (2004) 990-1000
-
(2004)
J Infect Dis
, vol.189
, Issue.6
, pp. 990-1000
-
-
Endy, T.P.1
Nisalak, A.2
Chunsuttitwat, S.3
Vaughn, D.W.4
Green, S.5
Ennis, F.A.6
-
19
-
-
0020574705
-
Complement receptor mediates enhanced flavivirus replication in macrophages
-
Cardosa M.J., Porterfield J.S., and Gordon S. Complement receptor mediates enhanced flavivirus replication in macrophages. J Exp Med 158 1 (1983) 258-263
-
(1983)
J Exp Med
, vol.158
, Issue.1
, pp. 258-263
-
-
Cardosa, M.J.1
Porterfield, J.S.2
Gordon, S.3
-
20
-
-
0014844884
-
Influence of immunological factors in respiratory syncytial virus disease
-
Chanock R.M., Kapikian A.Z., Mills J., Kim H.W., and Parrott R.H. Influence of immunological factors in respiratory syncytial virus disease. Arch Environ Health 21 3 (1970) 347-355
-
(1970)
Arch Environ Health
, vol.21
, Issue.3
, pp. 347-355
-
-
Chanock, R.M.1
Kapikian, A.Z.2
Mills, J.3
Kim, H.W.4
Parrott, R.H.5
-
21
-
-
0037446912
-
Antibody-dependent enhancement, a possible mechanism in augmented pulmonary disease of respiratory syncytial virus in the Bonnet monkey model
-
Ponnuraj E.M., Springer J., Hayward A.R., Wilson H., and Simoes E.A. Antibody-dependent enhancement, a possible mechanism in augmented pulmonary disease of respiratory syncytial virus in the Bonnet monkey model. J Infect Dis 187 8 (2003) 1257-1263
-
(2003)
J Infect Dis
, vol.187
, Issue.8
, pp. 1257-1263
-
-
Ponnuraj, E.M.1
Springer, J.2
Hayward, A.R.3
Wilson, H.4
Simoes, E.A.5
-
22
-
-
0038467640
-
Antibody-dependent enhancement of Ebola virus infection
-
Takada A., Feldmann H., Ksiazek T.G., and Kawaoka Y. Antibody-dependent enhancement of Ebola virus infection. J Virol 77 13 (2003) 7539-7544
-
(2003)
J Virol
, vol.77
, Issue.13
, pp. 7539-7544
-
-
Takada, A.1
Feldmann, H.2
Ksiazek, T.G.3
Kawaoka, Y.4
-
23
-
-
33748659233
-
Immunoglobulin g antibody-mediated enhancement of measles virus infection can bypass the protective antiviral immune response
-
Iankov I.D., Pandey M., Harvey M., Griesmann G.E., Federspiel M.J., and Russell S.J. Immunoglobulin g antibody-mediated enhancement of measles virus infection can bypass the protective antiviral immune response. J Virol 80 17 (2006) 8530-8540
-
(2006)
J Virol
, vol.80
, Issue.17
, pp. 8530-8540
-
-
Iankov, I.D.1
Pandey, M.2
Harvey, M.3
Griesmann, G.E.4
Federspiel, M.J.5
Russell, S.J.6
-
24
-
-
35548935103
-
Immunisation strategies for the management of severe acute respiratory syndrome (SARS)
-
Pletz M.W., Dickgreber N., Hagen L., Golpon H., Zabel P., Bauer T.T., et al. Immunisation strategies for the management of severe acute respiratory syndrome (SARS). Pneumologie 61 10 (2007) 663-667
-
(2007)
Pneumologie
, vol.61
, Issue.10
, pp. 663-667
-
-
Pletz, M.W.1
Dickgreber, N.2
Hagen, L.3
Golpon, H.4
Zabel, P.5
Bauer, T.T.6
-
25
-
-
0023567926
-
A human immunodeficiency virus type 1 (HIV-1) infection-enhancing factor in seropositive sera
-
Robinson Jr. W.E., Montefiori D.C., and Mitchell W.M. A human immunodeficiency virus type 1 (HIV-1) infection-enhancing factor in seropositive sera. Biochem Biophys Res Commun 149 2 (1987) 693-699
-
(1987)
Biochem Biophys Res Commun
, vol.149
, Issue.2
, pp. 693-699
-
-
Robinson Jr., W.E.1
Montefiori, D.C.2
Mitchell, W.M.3
-
26
-
-
0023935853
-
Antibody-dependent enhancement of human immunodeficiency virus type 1 infection
-
Robinson Jr. W.E., Montefiori D.C., and Mitchell W.M. Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. Lancet 1 8589 (1988) 790-794
-
(1988)
Lancet
, vol.1
, Issue.8589
, pp. 790-794
-
-
Robinson Jr., W.E.1
Montefiori, D.C.2
Mitchell, W.M.3
-
27
-
-
0026051133
-
Antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus type 1 infection in a human, Epstein-Barr virus-transformed B-lymphocytic cell line
-
Gras G.S., and Dormont D. Antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus type 1 infection in a human, Epstein-Barr virus-transformed B-lymphocytic cell line. J Virol 65 1 (1991) 541-545
-
(1991)
J Virol
, vol.65
, Issue.1
, pp. 541-545
-
-
Gras, G.S.1
Dormont, D.2
-
28
-
-
0024564268
-
Complement-mediated, antibody-dependent enhancement of HIV-1 infection in vitro is characterized by increased protein and RNA syntheses and infectious virus release
-
Robinson Jr. W.E., Montefiori D.C., Gillespie D.H., and Mitchell W.M. Complement-mediated, antibody-dependent enhancement of HIV-1 infection in vitro is characterized by increased protein and RNA syntheses and infectious virus release. J Acquir Immune Defic Syndr 2 1 (1989) 33-42
-
(1989)
J Acquir Immune Defic Syndr
, vol.2
, Issue.1
, pp. 33-42
-
-
Robinson Jr., W.E.1
Montefiori, D.C.2
Gillespie, D.H.3
Mitchell, W.M.4
-
29
-
-
0023803544
-
Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry
-
Takeda A., Tuazon C.U., and Ennis F.A. Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science 242 4878 (1988) 580-583
-
(1988)
Science
, vol.242
, Issue.4878
, pp. 580-583
-
-
Takeda, A.1
Tuazon, C.U.2
Ennis, F.A.3
-
30
-
-
0024390828
-
The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells
-
Homsy J., Meyer M., Tateno M., Clarkson S., and Levy J.A. The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells. Science 244 4910 (1989) 1357-1360
-
(1989)
Science
, vol.244
, Issue.4910
, pp. 1357-1360
-
-
Homsy, J.1
Meyer, M.2
Tateno, M.3
Clarkson, S.4
Levy, J.A.5
-
31
-
-
0025212678
-
Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals
-
Homsy J., Meyer M., and Levy J.A. Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals. J Virol 64 4 (1990) 1437-1440
-
(1990)
J Virol
, vol.64
, Issue.4
, pp. 1437-1440
-
-
Homsy, J.1
Meyer, M.2
Levy, J.A.3
-
32
-
-
34548496893
-
Fc receptor but not complement binding is important in antibody protection against HIV
-
Hessell A.J., Hangartner L., Hunter M., Havenith C.E., Beurskens F.J., Bakker J.M., et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449 7158 (2007) 101-104
-
(2007)
Nature
, vol.449
, Issue.7158
, pp. 101-104
-
-
Hessell, A.J.1
Hangartner, L.2
Hunter, M.3
Havenith, C.E.4
Beurskens, F.J.5
Bakker, J.M.6
-
33
-
-
0025253117
-
Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro
-
Robinson Jr. W.E., Kawamura T., Gorny M.K., Lake D., Xu J.Y., Matsumoto Y., et al. Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro. Proc Natl Acad Sci USA 87 8 (1990) 3185-3189
-
(1990)
Proc Natl Acad Sci USA
, vol.87
, Issue.8
, pp. 3185-3189
-
-
Robinson Jr., W.E.1
Kawamura, T.2
Gorny, M.K.3
Lake, D.4
Xu, J.Y.5
Matsumoto, Y.6
-
34
-
-
0025131885
-
Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro
-
Robinson Jr. W.E., Kawamura T., Lake D., Masuho Y., Mitchell W.M., and Hersh E.M. Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro. J Virol 64 11 (1990) 5301-5305
-
(1990)
J Virol
, vol.64
, Issue.11
, pp. 5301-5305
-
-
Robinson Jr., W.E.1
Kawamura, T.2
Lake, D.3
Masuho, Y.4
Mitchell, W.M.5
Hersh, E.M.6
-
35
-
-
0029044657
-
Interaction of complement and specific antibodies with the external glycoprotein 120 of HIV-1
-
Prohaszka Z., Hidvegi T., Ujhelyi E., Stoiber H., Dierich M.P., Susal C., et al. Interaction of complement and specific antibodies with the external glycoprotein 120 of HIV-1. Immunology 85 2 (1995) 184-189
-
(1995)
Immunology
, vol.85
, Issue.2
, pp. 184-189
-
-
Prohaszka, Z.1
Hidvegi, T.2
Ujhelyi, E.3
Stoiber, H.4
Dierich, M.P.5
Susal, C.6
-
36
-
-
0025861673
-
Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro
-
Robinson Jr. W.E., Gorny M.K., Xu J.Y., Mitchell W.M., and Zolla-Pazner S. Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro. J Virol 65 8 (1991) 4169-4176
-
(1991)
J Virol
, vol.65
, Issue.8
, pp. 4169-4176
-
-
Robinson Jr., W.E.1
Gorny, M.K.2
Xu, J.Y.3
Mitchell, W.M.4
Zolla-Pazner, S.5
-
37
-
-
0032556957
-
Inactivation of a common epitope responsible for the induction of antibody-dependent enhancement of HIV
-
Mitchell W.M., Ding L., and Gabriel J. Inactivation of a common epitope responsible for the induction of antibody-dependent enhancement of HIV. Aids 12 2 (1998) 147-156
-
(1998)
Aids
, vol.12
, Issue.2
, pp. 147-156
-
-
Mitchell, W.M.1
Ding, L.2
Gabriel, J.3
-
38
-
-
33750952525
-
Mechanism for complement-mediated, antibody-dependent enhancement of human immunodeficiency virus type 1 infection in MT2 cells is enhanced entry through CD4, CD21, and CXCR4 chemokine receptors
-
Robinson W.E. Mechanism for complement-mediated, antibody-dependent enhancement of human immunodeficiency virus type 1 infection in MT2 cells is enhanced entry through CD4, CD21, and CXCR4 chemokine receptors. Viral Immunol 19 3 (2006) 434-447
-
(2006)
Viral Immunol
, vol.19
, Issue.3
, pp. 434-447
-
-
Robinson, W.E.1
-
39
-
-
8244253673
-
Two parallel routes of the complement-mediated antibody-dependent enhancement of HIV-1 infection
-
Prohaszka Z., Nemes J., Hidvegi T., Toth F.D., Kerekes K., Erdei A., et al. Two parallel routes of the complement-mediated antibody-dependent enhancement of HIV-1 infection. Aids 11 8 (1997) 949-958
-
(1997)
Aids
, vol.11
, Issue.8
, pp. 949-958
-
-
Prohaszka, Z.1
Nemes, J.2
Hidvegi, T.3
Toth, F.D.4
Kerekes, K.5
Erdei, A.6
-
40
-
-
0028374065
-
Passive immunization of macaques against SIV infection
-
Gardner M.B., Rosenthal A., Jennings M., Yee J.A., Antipa L., and MacKenzie M. Passive immunization of macaques against SIV infection. J Med Primatol 23 2-3 (1994) 164-174
-
(1994)
J Med Primatol
, vol.23
, Issue.2-3
, pp. 164-174
-
-
Gardner, M.B.1
Rosenthal, A.2
Jennings, M.3
Yee, J.A.4
Antipa, L.5
MacKenzie, M.6
-
41
-
-
0029022873
-
Passive immunization of rhesus macaques against SIV infection and disease
-
Gardner M., Rosenthal A., Jennings M., Yee J., Antipa L., and Robinson Jr. E. Passive immunization of rhesus macaques against SIV infection and disease. AIDS Res Hum Retroviruses 11 7 (1995) 843-854
-
(1995)
AIDS Res Hum Retroviruses
, vol.11
, Issue.7
, pp. 843-854
-
-
Gardner, M.1
Rosenthal, A.2
Jennings, M.3
Yee, J.4
Antipa, L.5
Robinson Jr., E.6
-
42
-
-
0028861341
-
Antibodies to the putative SIV infection-enhancing domain diminish beneficial effects of an SIV gp160 vaccine in rhesus macaques
-
Mitchell W.M., Torres J., Johnson P.R., Hirsch V., Yilma T., Gardner M.B., et al. Antibodies to the putative SIV infection-enhancing domain diminish beneficial effects of an SIV gp160 vaccine in rhesus macaques. Aids 9 1 (1995) 27-34
-
(1995)
Aids
, vol.9
, Issue.1
, pp. 27-34
-
-
Mitchell, W.M.1
Torres, J.2
Johnson, P.R.3
Hirsch, V.4
Yilma, T.5
Gardner, M.B.6
-
43
-
-
0036263196
-
Comparison of human immunodeficiency virus (HIV)-specific infection-enhancing and -inhibiting antibodies in AIDS patients
-
Subbramanian R.A., Xu J., Toma E., Morisset R., Cohen E.A., Menezes J., et al. Comparison of human immunodeficiency virus (HIV)-specific infection-enhancing and -inhibiting antibodies in AIDS patients. J Clin Microbiol 40 6 (2002) 2141-2146
-
(2002)
J Clin Microbiol
, vol.40
, Issue.6
, pp. 2141-2146
-
-
Subbramanian, R.A.1
Xu, J.2
Toma, E.3
Morisset, R.4
Cohen, E.A.5
Menezes, J.6
-
44
-
-
0025796729
-
Neutralizing and complement-dependent enhancing antibodies in different stages of HIV infection
-
Toth F.D., Szabo B., Ujhelyi E., Paloczi K., Horvath A., Fust G., et al. Neutralizing and complement-dependent enhancing antibodies in different stages of HIV infection. Aids 5 3 (1991) 263-268
-
(1991)
Aids
, vol.5
, Issue.3
, pp. 263-268
-
-
Toth, F.D.1
Szabo, B.2
Ujhelyi, E.3
Paloczi, K.4
Horvath, A.5
Fust, G.6
-
45
-
-
2442764677
-
Strong correlation between the complement-mediated antibody-dependent enhancement of HIV-1 infection and plasma viral load
-
Szabo J., Prohaszka Z., Toth F.D., Gyuris A., Segesdi J., Banhegyi D., et al. Strong correlation between the complement-mediated antibody-dependent enhancement of HIV-1 infection and plasma viral load. Aids 13 14 (1999) 1841-1849
-
(1999)
Aids
, vol.13
, Issue.14
, pp. 1841-1849
-
-
Szabo, J.1
Prohaszka, Z.2
Toth, F.D.3
Gyuris, A.4
Segesdi, J.5
Banhegyi, D.6
-
46
-
-
0028269618
-
Neutralizing and enhancing antibodies measured in complement-restored serum samples from HIV-1-infected individuals correlate with immunosuppression and disease
-
Fust G., Toth F.D., Kiss J., Ujhelyi E., Nagy I., and Banhegyi D. Neutralizing and enhancing antibodies measured in complement-restored serum samples from HIV-1-infected individuals correlate with immunosuppression and disease. Aids 8 5 (1994) 603-609
-
(1994)
Aids
, vol.8
, Issue.5
, pp. 603-609
-
-
Fust, G.1
Toth, F.D.2
Kiss, J.3
Ujhelyi, E.4
Nagy, I.5
Banhegyi, D.6
-
47
-
-
0142042944
-
Significant decrease of the enhancement/neutralization index in HIV patients during highly active antiretroviral therapy (HAART)
-
Banhegyi D., Bacsi A., Toth F.D., Prohaszka Z., Horvath A., Beck Z., et al. Significant decrease of the enhancement/neutralization index in HIV patients during highly active antiretroviral therapy (HAART). Immunol Lett 89 1 (2003) 25-30
-
(2003)
Immunol Lett
, vol.89
, Issue.1
, pp. 25-30
-
-
Banhegyi, D.1
Bacsi, A.2
Toth, F.D.3
Prohaszka, Z.4
Horvath, A.5
Beck, Z.6
-
48
-
-
0025804179
-
Absence of a clinical correlation for complement-mediated, infection-enhancing antibodies in plasma or sera from HIV-1-infected individuals. Multicenter AIDS Cohort Study Group
-
Montefiori D.C., Lefkowitz Jr. L.B., Keller R.E., Holmberg V., Sandstrom E., and Phair J.P. Absence of a clinical correlation for complement-mediated, infection-enhancing antibodies in plasma or sera from HIV-1-infected individuals. Multicenter AIDS Cohort Study Group. Aids 5 5 (1991) 513-517
-
(1991)
Aids
, vol.5
, Issue.5
, pp. 513-517
-
-
Montefiori, D.C.1
Lefkowitz Jr., L.B.2
Keller, R.E.3
Holmberg, V.4
Sandstrom, E.5
Phair, J.P.6
-
49
-
-
0030057730
-
Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors
-
Montefiori D.C., Pantaleo G., Fink L.M., Zhou J.T., Zhou J.Y., Bilska M., et al. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J Infect Dis 173 1 (1996) 60-67
-
(1996)
J Infect Dis
, vol.173
, Issue.1
, pp. 60-67
-
-
Montefiori, D.C.1
Pantaleo, G.2
Fink, L.M.3
Zhou, J.T.4
Zhou, J.Y.5
Bilska, M.6
-
50
-
-
0034385414
-
Macaque immunization with virions purified from a primary isolate of the human immunodeficiency virus type 1 induced enhancement antibodies
-
discussion 85-7
-
Verrier F., Moog C., Barre-Sinoussi F., Van der Ryst E., Spenlehauer C., and Girard M. Macaque immunization with virions purified from a primary isolate of the human immunodeficiency virus type 1 induced enhancement antibodies. Bull Acad Natl Med 184 1 (2000) 67-84 discussion 85-7
-
(2000)
Bull Acad Natl Med
, vol.184
, Issue.1
, pp. 67-84
-
-
Verrier, F.1
Moog, C.2
Barre-Sinoussi, F.3
Van der Ryst, E.4
Spenlehauer, C.5
Girard, M.6
-
51
-
-
2442689092
-
Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies
-
Haigwood N.L., Montefiori D.C., Sutton W.F., McClure J., Watson A.J., Voss G., et al. Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies. J Virol 78 11 (2004) 5983-5995
-
(2004)
J Virol
, vol.78
, Issue.11
, pp. 5983-5995
-
-
Haigwood, N.L.1
Montefiori, D.C.2
Sutton, W.F.3
McClure, J.4
Watson, A.J.5
Voss, G.6
-
52
-
-
4444316121
-
Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein
-
Staprans S.I., Barry A.P., Silvestri G., Safrit J.T., Kozyr N., Sumpter B., et al. Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. Proc Natl Acad Sci USA 101 35 (2004) 13026-13031
-
(2004)
Proc Natl Acad Sci USA
, vol.101
, Issue.35
, pp. 13026-13031
-
-
Staprans, S.I.1
Barry, A.P.2
Silvestri, G.3
Safrit, J.T.4
Kozyr, N.5
Sumpter, B.6
-
53
-
-
0028670689
-
Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network
-
Keefer M.C., Graham B.S., Belshe R.B., Schwartz D., Corey L., Bolognesi D.P., et al. Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network. AIDS Res Hum Retroviruses 10 12 (1994) 1713-1723
-
(1994)
AIDS Res Hum Retroviruses
, vol.10
, Issue.12
, pp. 1713-1723
-
-
Keefer, M.C.1
Graham, B.S.2
Belshe, R.B.3
Schwartz, D.4
Corey, L.5
Bolognesi, D.P.6
-
54
-
-
0026019644
-
The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network
-
Dolin R., Graham B.S., Greenberg S.B., Tacket C.O., Belshe R.B., Midthun K., et al. The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network. Ann Intern Med 114 2 (1991) 119-127
-
(1991)
Ann Intern Med
, vol.114
, Issue.2
, pp. 119-127
-
-
Dolin, R.1
Graham, B.S.2
Greenberg, S.B.3
Tacket, C.O.4
Belshe, R.B.5
Midthun, K.6
-
55
-
-
13944250922
-
Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial
-
Gilbert P.B., Peterson M.L., Follmann D., Hudgens M.G., Francis D.P., Gurwith M., et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 191 5 (2005) 666-677
-
(2005)
J Infect Dis
, vol.191
, Issue.5
, pp. 666-677
-
-
Gilbert, P.B.1
Peterson, M.L.2
Follmann, D.3
Hudgens, M.G.4
Francis, D.P.5
Gurwith, M.6
-
56
-
-
13944262072
-
Lessons from failure - preparing for future HIV-1 vaccine efficacy trials
-
Graham B.S., and Mascola J.R. Lessons from failure - preparing for future HIV-1 vaccine efficacy trials. J Infect Dis 191 5 (2005) 647-649
-
(2005)
J Infect Dis
, vol.191
, Issue.5
, pp. 647-649
-
-
Graham, B.S.1
Mascola, J.R.2
|